Rocket Pharmaceuticals, Inc.
RCKTDrugs in Pipeline
2
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
RCKT Earnings Report
EPS Est: $0.28 | FQ end 2026-06
Q1 earnings miss
How RCKT's past catalysts played out
Fanconi Anemia Complementation Group A
1 drug in this indication
Leukocyte Adhesion Defect - Type I
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Rocket Pharmaceuticals, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Rocket Pharmaceuticals, Inc.'s (RCKT) pipeline across Phase 2. Its lead program is RP-L201 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Rocket Pharmaceuticals, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Rocket Pharmaceuticals, Inc. (RCKT) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track RCKT biotech catalysts?→
Add RCKT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Rocket Pharmaceuticals, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.